Cacha Peeters-Scholte

List of Publications by Year
in descending order

44 papers	1,051 citations	430874 18 h-index	434195 31 g-index
46 all docs	46 docs citations	46 times ranked	1448 citing authors

#	Article	IF	Citations
1	Combining advanced MRI and EEG techniques better explains long-term motor outcome after very preterm birth. Pediatric Research, 2022, 91, 1874-1881.	2.3	2
2	Prenatal exome sequencing: A useful tool for the fetal neurologist. Clinical Genetics, 2022, 101, 65-77.	2.0	14
3	Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy. Brain, 2022, 145, 2301-2312.	7.6	8
4	Intracerebral hemorrhage in a neonate with an intragenic COL4A2 duplication. American Journal of Medical Genetics, Part A, 2021, 185, 571-574.	1.2	4
5	Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism. American Journal of Human Genetics, 2021, 108, 1138-1150.	6.2	17
6	Longitudinal Follow-Up of Children Born Preterm: Neurodevelopment From 2 to 10 Years of Age. Frontiers in Pediatrics, 2021, 9, 674221.	1.9	5
7	Associations between Neonatal Magnetic Resonance Imaging and Short- and Long-Term Neurodevelopmental Outcomes in a Longitudinal Cohort of Very Preterm Children. Journal of Pediatrics, 2021, 234, 46-53.e2.	1.8	16
8	Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome. Genetics in Medicine, 2021, 23, 2122-2137.	2.4	16
9	Clustered mutations in the GRIK2 kainate receptor subunit gene underlie diverse neurodevelopmental disorders. American Journal of Human Genetics, 2021, 108, 1692-1709.	6.2	18
10	Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatric Research, 2020, 87, 689-696.	2.3	14
11	Classroom-evaluated school performance at nine years of age after very preterm birth. Early Human Development, 2020, 140, 104834.	1.8	4
12	First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects. Current Clinical Pharmacology, 2020, 15, 152-163.	0.6	3
13	The degree of prematurity affects functional brain activity in preterm born children at school-age: An EEG study. Early Human Development, 2020, 148, 105096.	1.8	4
14	Translation from animal to clinical studies, choosing the optimal moment. Pediatric Research, 2020, 88, 836-837.	2.3	1
15	A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country. Paediatric Drugs, 2020, 22, 95-104.	3.1	6
16	From diagnostic yield to clinical impact: a pilot study on the implementation of prenatal exome sequencing in routine care. Genetics in Medicine, 2019, 21, 2303-2310.	2.4	41
17	Neuroprotective strategies following perinatal hypoxia-ischemia: TakingÂaim at NOS. Free Radical Biology and Medicine, 2019, 142, 123-131.	2.9	33
18	De Novo Mutations Affecting the Catalytic CÎ± Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders. American Journal of Human Genetics, 2019, 104, 139-156.	6.2	39

#	Article	IF	Citations
19	Putting genome-wide sequencing in neonates into perspective. Genetics in Medicine, 2019, 21, 1074-1082.	2.4	15
20	Observational study shows that it is feasible to provide neuroprotective treatment for neonatal encephalopathy in lowâ€income countries. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 1345-1349.	1.5	4
21	2-Iminobiotin Superimposed on Hypothermia Protects Human Neuronal Cells from Hypoxia-Induced Cell Damage: An in Vitro Study. Frontiers in Pharmacology, 2018, 8, 971.	3.5	9
22	Nitric Oxide Synthase Inhibition as a Neuroprotective Strategy Following Hypoxicâ€“Ischemic Encephalopathy: Evidence From Animal Studies. Frontiers in Neurology, 2018, 9, 258.	2.4	31
23	Genotype-phenotype correlation in ATAD3A deletions: not just of scientific relevance. Brain, 2017, 140, e66-e66.	7.6	24
24	Fetal brain imaging in isolated congenital heart defects â€“ a systematic review and metaâ€analysis. Prenatal Diagnosis, 2016, 36, 601-613.	2.3	30
25	Insights into the neuroprotective mechanisms of 2-iminobiotin employing an in-vitro model of hypoxic-ischemic cell injury. European Journal of Pharmacology, 2016, 792, 63-69.	3.5	11
26	Polyhydramnios and cerebellar atrophy: a prenatal presentation of mitochondrial encephalomyopathy caused by mutations in the FBXL 4 gene. Clinical Case Reports (discontinued), 2016, 4, 425-428.	0.5	18
27	De novo loss-of-function mutations in WAC cause a recognizable intellectual disability syndrome and learning deficits in Drosophila. European Journal of Human Genetics, 2016, 24, 1145-1153.	2.8	34
28	Clinical and molecular characterization of an infant with a tandem duplication and deletion of 19p13. American Journal of Medical Genetics, Part A, 2015, 167, 1884-1889.	1.2	4
29	Intra-Arterial Treatment in a Child with Embolic Stroke Due to Atrial Myxoma. Interventional Neuroradiology, 2014, 20, 345-351.	1.1	27
30	Comments on â€˜Infantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizuresâ€™ in Molecular Genetics and Metabolism' 2014 Mar;111(3):404-7 by M.G. de Roo, N.G. Abeling, C.B. Majoie, A.M. Bosch, J.H. Koelman, J.M. Cobben, M. Duran, B.T. Poll-The. Molecular Genetics and Metabolism Reports, 2014, 1, 220-222.	1.1	0
31	Short-Term Doseâ€“Response Characteristics of 2-Iminobiotin Immediately Postinsult in the Neonatal Piglet After Hypoxia-Ischemia. Stroke, 2013, 44, 809-811.	2.0	25
32	<scp>GPSM</scp>2 and Chudleyâ€“<scp>M</scp>c<scp>C</scp>ullough Syndrome: A Dutch Founder Variant Brought to North America. American Journal of Medical Genetics, Part A, 2013, 161, 973-976.	1.2	13
33	A fatal course of neonatal meningo-encephalitis. Journal of Clinical Virology, 2012, 55, 91-94.	3.1	3
34	Increased concentrations of both NMDA receptor co-agonists d-serine and glycine in global ischemia: a potential novel treatment target for perinatal asphyxia. Amino Acids, 2012, 43, 355-363.	2.7	22
35	Chronological changes of the amplitudeâ€integrated EEG in a neonate with molybdenum cofactor deficiency. Journal of Inherited Metabolic Disease, 2010, 33, 401-407.	3.6	11
36	Long-Term Neuroprotection with 2-Iminobiotin, An Inhibitor of Neuronal and Inducible Nitric Oxide Synthase, after Cerebral Hypoxia-Ischemia in Neonatal Rats. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 67-74.	4.3	65

#	Article	IF	Citations
37	Nitrosylation precedes caspase-3 activation and translocation of apoptosis-inducing factor in neonatal rat cerebral hypoxia-ischaemia. Journal of Neurochemistry, 2004, 90, 462-471.	3.9	77
38	Redox state of near infrared spectroscopy-measured cytochrome aa3 correlates with delayed cerebral energy failure following perinatal hypoxia-ischaemia in the newborn pig. Experimental Brain Research, 2004, 156, 20-26.	1.5	21
39	Effects of Allopurinol and Deferoxamine on Reperfusion Injury of the Brain in Newborn Piglets after Neonatal Hypoxia-Ischemia. Pediatric Research, 2003, 54, 516-522.	2.3	112
40	Neuroprotection by Selective Nitric Oxide Synthase Inhibition at 24 Hours After Perinatal Hypoxia-Ischemia. Stroke, 2002, 33, 2304-2310.	2.0	118
41	Effects of Selective Nitric Oxide Synthase Inhibition on IGF-1, Caspases and Cytokines in a Newborn Piglet Model of Perinatal Hypoxia-Ischaemia. Developmental Neuroscience, 2002, 24, 396-404.	2.0	24
42	Inhibition of nNOS and iNOS following Hypoxia-Ischaemia Improves Long-Term Outcome but Does Not Influence the Inflammatory Response in the Neonatal Rat Brain. Developmental Neuroscience, 2002, 24, 389-395.	2.0	34
43	Changes in cerebral haemodynamics, regional oxygen saturation and amplitude-integrated continuous EEG during hypoxia-ischaemia and reperfusion in newborn piglets. Experimental Brain Research, 2002, 144, 172-177.	1.5	28
44	Pharmacological interventions in the newborn piglet in the first 24 h after hypoxia-ischemia. Experimental Brain Research, 2002, 147, 200-208.	1.5	34